Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nathan den Broeder

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Rheumatology (Oxford, England)|October 5, 2023
Therapy with JAK inhibitors or bDMARDs and the risk of cardiovascular events in the Dutch rheumatoid arthritis populationCalin D Popa, Merel A A Opdam, Nathan den Broeder, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 26, 2022
Quality of Surveillance Impacts the Colitis-Associated Advanced Neoplasia Risk: A Multicenter Case-Control StudyMaarten Te Groen, Monica Derks, Nathan den Broeder, et al.
RMD Open|April 17, 2018
Predictive value of serum calprotectin (S100A8/A9) for clinical response after starting or tapering anti-TNF treatment in patients with rheumatoid arthritisLieke Tweehuysen, Nathan den Broeder, Noortje van Herwaarden, et al.
Rheumatology (Oxford, England)|June 13, 2024
Effect of using the Simple Erosion Narrowing Score or Sharp/van der Heijde score on the power of rheumatoid arthritis clinical trials to detect differences in radiographic progressionNathan den Broeder, Thomas E Bolhuis, Noortje van Herwaarden, et al.
Rheumatology (Oxford, England)|December 20, 2022
The added value of predictive biomarkers in treat-to-target strategies for rheumatoid arthritis patients: a conceptual modelling studyMaike H M Wientjes, Evy Ulijn, Wietske Kievit, et al.
Annals of the Rheumatic Diseases|August 29, 2018
Three-year cost-effectiveness analysis of the DRESS study: protocolised tapering is keyNathan den Broeder, Chantal A M Bouman, Wietske Kievit, et al.
RMD Open|April 10, 2024
Long-term clinical and radiological effectiveness and safety of ultralow doses of rituximab in rheumatoid arthritis: observational extension of the REDO trialNathan den Broeder, Lise Verhoef, Yaël A de Man, et al.
The Lancet. Rheumatology|January 30, 2024
Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis (COMPLETE-PsA): a double-blind, placebo-controlled, randomised, trialMichelle L M Mulder, Johanna E Vriezekolk, Tamara W van Hal, et al.
Rheumatology (Oxford, England)|June 10, 2022
Rituximab dose-dependent infection risk in rheumatoid arthritis is not mediated through circulating immunoglobulins, neutrophils or B cellsMerel A A Opdam, J H de Leijer, Nathan den Broeder, et al.
Trials|January 17, 2020
Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trialCelia A J Michielsens, Nadine Boers, Nathan den Broeder, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Rheumatology (Oxford, England)|October 5, 2023
Therapy with JAK inhibitors or bDMARDs and the risk of cardiovascular events in the Dutch rheumatoid arthritis populationCalin D Popa, Merel A A Opdam, Nathan den Broeder, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 26, 2022
Quality of Surveillance Impacts the Colitis-Associated Advanced Neoplasia Risk: A Multicenter Case-Control StudyMaarten Te Groen, Monica Derks, Nathan den Broeder, et al.
RMD Open|April 17, 2018
Predictive value of serum calprotectin (S100A8/A9) for clinical response after starting or tapering anti-TNF treatment in patients with rheumatoid arthritisLieke Tweehuysen, Nathan den Broeder, Noortje van Herwaarden, et al.
Rheumatology (Oxford, England)|June 13, 2024
Effect of using the Simple Erosion Narrowing Score or Sharp/van der Heijde score on the power of rheumatoid arthritis clinical trials to detect differences in radiographic progressionNathan den Broeder, Thomas E Bolhuis, Noortje van Herwaarden, et al.
Rheumatology (Oxford, England)|December 20, 2022
The added value of predictive biomarkers in treat-to-target strategies for rheumatoid arthritis patients: a conceptual modelling studyMaike H M Wientjes, Evy Ulijn, Wietske Kievit, et al.
Annals of the Rheumatic Diseases|August 29, 2018
Three-year cost-effectiveness analysis of the DRESS study: protocolised tapering is keyNathan den Broeder, Chantal A M Bouman, Wietske Kievit, et al.
RMD Open|April 10, 2024
Long-term clinical and radiological effectiveness and safety of ultralow doses of rituximab in rheumatoid arthritis: observational extension of the REDO trialNathan den Broeder, Lise Verhoef, Yaël A de Man, et al.
The Lancet. Rheumatology|January 30, 2024
Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis (COMPLETE-PsA): a double-blind, placebo-controlled, randomised, trialMichelle L M Mulder, Johanna E Vriezekolk, Tamara W van Hal, et al.
Rheumatology (Oxford, England)|June 10, 2022
Rituximab dose-dependent infection risk in rheumatoid arthritis is not mediated through circulating immunoglobulins, neutrophils or B cellsMerel A A Opdam, J H de Leijer, Nathan den Broeder, et al.
Trials|January 17, 2020
Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trialCelia A J Michielsens, Nadine Boers, Nathan den Broeder, et al.
Pageof 6